Shares of Merck & Company, Inc. (MRK) traded 0.1 points or 0.16% higher at $62.09.The total intraday money flow for the shares came in at a disappointing $(-25.77) million. The total upticks amounted to $97.73 million and the total downticks were approximately $123.5 million, with the up/down ratio of 0.79. On a different note, the shares have seen 0.55% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $4.24 million in upticks and an outflow of $33.12 million in downticks. The up/down ratio for the block was found to be 0.13. The net money flow for the block transaction was $(-28.88) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Merck & Co., Inc. rose by 1.67% in the last five trading days and 5.49% for the last 4 weeks. Merck & Co., Inc. is up 6.57% in the last 3-month period. Year-to-Date the stock performance stands at 5.49%. Merck & Company, Inc. (NYSE:MRK) rose 0.18% or 0.11 points on Wednesday and made its way into the gainers of the day. After trading began at $62.06 the stock was seen hitting $62.27 as a peak level and $61.56 as the lowest level. The stock ended up at $62.1. The daily volume was measured at 11,018,765 shares. The 52-week high of the share price is $65.46 and the 52-week low is $47.97. The company has a market cap of $171,218 million.
Company has reported several Insider transactions to the SEC, on Jan 17, 2017, Wendell P Weeks (director) sold 100 shares at 31.35 per share price.On Nov 10, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 140,000 shares at 65.02 per share price.On Nov 8, 2016, Julie L. Gerberding (EVP Strat Comm, Gl Pub Policy) sold 85,523 shares at 60.02 per share price.
Merck & Co. Last issued its quarterly earnings results on Oct 25, 2016. The company reported $1.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.08. Analyst had a consensus of $0.99. The company had revenue of $10536.00 million for the quarter, compared to analysts expectations of $10178.17 million. The companys revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.96 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Merck & Co. was Initiated by Bryan Garnier to Buy on Jan 13, 2017. Merck & Co. was Upgraded by Piper Jaffray to Overweight on Jan 12, 2017. Merck & Co. was Upgraded by Morgan Stanley to Overweight on Jan 12, 2017. Merck & Co. was Upgraded by Guggenheim to Buy on Jan 12, 2017. Merck & Co. was Downgraded by Jefferies to Underperform on Dec 19, 2016.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.